PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393489
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393489
The global pharmacogenetic testing market is expected to reach USD 11,442.40 million by 2030 from USD 5,960.00 million in 2022, growing at a CAGR of 8.7% during the forecast period of 2023 to 2030.
Global Pharmacogenetic Testing Market, By Type (Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, and Single Gene Tests), Gene Type (CYP2C19, CYP2D6, CYP2C9 AND VKORC1, CYP1A2, HLA-B*1502, HLA-B*5701, CYP2D, OPRM1, ONCOTYPE DX AND MAMMAPRINT, DRD3, D4D4, SLC6A4, HTR2A/C, TMPT, and Others), Drug Type (Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, and Over-the-Counter Medications), Sample (Blood and Saliva), Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology, and Others), Application (Clinical Practice, Drug Development, and Drug Regulation), End User (Healthcare Providers, Pharmaceutical & Biotechnology Companies, Research Centres and Academic Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, and Direct-to-Customer Services), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, rest of Middle East and Africa) - Industry Trends and Forecast to 2030.